Eric Lefkofsky, Founder and CEO of Tempus, shared Tempus AI’s post on LinkedIn, adding:
“Sequencing is no longer just about matching a patient to an existing treatment – with individualized therapies, it’s becoming an integral part of the treatment itself.
Tempus is at the forefront of this transition. By expanding our collaboration with Merck and Moderna, we are building the real-world clinical and diagnostic infrastructure this new era of personalized medicine requires.”
Quoting Tempus AI:
“Today we announced an expanded collaboration with both Moderna and Merck to support the potential commercialization of intismeran autogene, a novel individualized neoantigen therapy.
Tempus will deliver advanced NGS sequencing and sample collection workflows, combining our clinical infrastructure with mRNA innovation to help bring personalized cancer vaccines to patients at scale.”
Read the full announcement here.
Read more articles about Tempus AI on OncoDaily.